Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2018, Article ID 8363295, 11 pages
https://doi.org/10.1155/2018/8363295
Research Article

Exploring the Mechanism of Danshen against Myelofibrosis by Network Pharmacology and Molecular Docking

1College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250014, Shandong, China
2College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250014, Shandong, China
3Department of Oncology, Weifang Traditional Chinese Hospital, Weifang 261041, Shandong, China
4College of Basic Medicine, Qingdao University, 308 Ningxia Road, Qingdao 266071, Shandong, China

Correspondence should be addressed to Changgang Sun; moc.621@rotcodgcs

Received 26 July 2018; Revised 19 October 2018; Accepted 12 November 2018; Published 5 December 2018

Academic Editor: Takao Namiki

Copyright © 2018 Jie Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Fan, Y. Tang, Z. Wu et al., “Elevated expression of the EZH2 gene in CALR-mutated patients with primary myelofibrosis,” Annals of Hematology, vol. 97, no. 7, pp. 1193–1208, 2018. View at Publisher · View at Google Scholar
  2. N. Lavi, J. M. Rowe, and T. Zuckerman, “Allogeneic stem-cell transplantation for myelofibrosis,” Current Opinion in Hematology, vol. 24, no. 6, pp. 475–480, 2017. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Pettit and O. Odenike, “Novel Therapies for Myelofibrosis,” Current Heart Failure Reports, vol. 12, no. 6, pp. 611–624, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Mascarenhas, R. Hoffman, M. Talpaz et al., “Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis,” JAMA Oncology, vol. 4, no. 5, p. 652, 2018. View at Publisher · View at Google Scholar
  5. D. Tremblay, B. Marcellino, and J. Mascarenhas, “Pharmacotherapy of Myelofibrosis,” Drugs, vol. 77, no. 14, pp. 1549–1563, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. X. Xu, H. Lv, X. Li, H. Su, X. Zhang, and J. Yang, “Danshen attenuates cartilage injuries in osteoarthritis in vivo and in vitro by activating JAK2/STAT3 and AKT pathways,” Journal of Experimental Animal Science, vol. 67, no. 2, pp. 127–137, 2018. View at Publisher · View at Google Scholar
  7. Z. Li, S. Xu, and P. Liu, “Salvia miltiorrhizaBurge (Danshen): a golden herbal medicine in cardiovascular therapeutics,” Acta Pharmacologica Sinica, vol. 39, no. 5, pp. 802–824, 2018. View at Publisher · View at Google Scholar
  8. T. Uto, N. H. Tung, T. Ohta et al., “Antiproliferative activity and apoptosis induction by trijuganone C isolated from the root of Salvia miltiorrhiza Bunge (Danshen),” Phytotherapy Research, vol. 32, no. 4, pp. 657–666, 2018. View at Google Scholar · View at Scopus
  9. Q. Tian, C. Ding, S. Song, Y. Wang, A. Zhang, and Z. Miao, “New tanshinone I derivatives S222 and S439 similarly inhibit topoisomerase I/II but reveal different p53-dependency in inducing G2/M arrest and apoptosis,” Biochemical Pharmacology, vol. 154, pp. 255–264, 2018. View at Publisher · View at Google Scholar
  10. S. Buyanravjikh, S. Han, S. Lee et al., “Cryptotanshinone inhibits IgE-mediated degranulation through inhibition of spleen tyrosine kinase and tyrosine-protein kinase phosphorylation in mast cells,” Molecular Medicine Reports, 2018. View at Publisher · View at Google Scholar
  11. X. Wang, S. L. Morris-Natschke, and K.-H. Lee, “New developments in the chemistry and biology of the bioactive constituents of tanshen,” Medicinal Research Reviews, vol. 27, no. 1, pp. 133–148, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Xu, H. Lv, X. Li, H. Su, X. Zhang, and J. Yang, “Danshen attenuates osteoarthritis-related cartilage degeneration through inhibition of NF-κB signaling pathway in vivo and in vitro,” The International Journal of Biochemistry & Cell Biology, vol. 95, no. 6, pp. 644–651, 2017. View at Publisher · View at Google Scholar
  13. X. Liu, J. Wu, D. Zhang, K. Wang, X. Duan, and X. Zhang, “A Network Pharmacology Approach to Uncover the Multiple Mechanisms of Hedyotis diffusa Willd. on Colorectal Cancer,” Evidence-Based Complementary and Alternative Medicine, vol. 2018, Article ID 6517034, 12 pages, 2018. View at Publisher · View at Google Scholar
  14. L. Zeng, K. Yang, and J. Ge, “Uncovering the Pharmacological Mechanism of Astragalus Salvia Compound on Pregnancy-Induced Hypertension Syndrome by a Network Pharmacology Approach,” Scientific Reports, vol. 7, no. 1, 2017. View at Publisher · View at Google Scholar
  15. H. Liu, L. Zeng, K. Yang, and G. Zhang, “A Network Pharmacology Approach to Explore the Pharmacological Mechanism of Xiaoyao Powder on Anovulatory Infertility,” Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 2960372, 13 pages, 2016. View at Publisher · View at Google Scholar
  16. M. Cheng and Z. Chen, “Trypsin inhibitor screening in traditional Chinese medicine by using an immobilized enzyme microreactor in capillary and molecular docking study,” Journal of Separation Science, vol. 40, no. 15, pp. 3168–3174, 2017. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Chen, J. Du, Q. Dai, H. Zhang, W. Pang, and J. Hu, “Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking,” European Journal of Medicinal Chemistry, vol. 83, pp. 294–306, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Hsin, Y. Matsuoka, Y. Asai et al., “systemsDock: a web server for network pharmacology-based prediction and analysis,” Nucleic Acids Research, vol. 44, no. W1, pp. W507–W513, 2016. View at Publisher · View at Google Scholar
  19. A. L. Hopkins, “Network pharmacology: the next paradigm in drug discovery,” Nature Chemical Biology, vol. 4, no. 11, pp. 682–690, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. M. W. El-Saadi, T. Williams-Hart, B. A. Salvatore, and E. Mahdavian, “Use of in-silico assays to characterize the ADMET profile and identify potential therapeutic targets of fusarochromanone, a novel anti-cancer agent,” In Silico Pharmacology, vol. 3, no. 1, 2015. View at Publisher · View at Google Scholar
  21. J. Gao, L. Liang, Y. Zhu, S. Qiu, T. Wang, and L. Zhang, “Ligand and structure-based approaches for the identification of peptide deformylase inhibitors as antibacterial drugs,” International Journal of Molecular Sciences, vol. 17, no. 7, article no. 1141, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. Q. Kong, Y. Ma, J. Yu, and X. Chen, “Predicted molecular targets and pathways for germacrone, curdione, and furanodiene in the treatment of breast cancer using a bioinformatics approach,” Scientific Reports, vol. 7, no. 1, 2017. View at Google Scholar · View at Scopus
  23. J. M. O'Sullivan and C. N. Harrison, “Myelofibrosis: clinicopathologic features, prognosis, and management,” Clin Adv Hematol Oncol, vol. 16, no. 12, pp. 121–131.
  24. T. Barbui, J. Thiele, H. Gisslinger et al., “The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion,” Blood Cancer Journal, vol. 8, no. 2, 2018. View at Publisher · View at Google Scholar
  25. A. Montaño, M. Forero-Castro, D. Marchena-Mendoza, R. Benito, and J. Hernández-Rivas, “New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update,” Cancers, vol. 10, no. 4, p. 110, 2018. View at Publisher · View at Google Scholar
  26. G. Blandino and S. Di Agostino, “New therapeutic strategies to treat human cancers expressing mutant p53 proteins,” Journal of Experimental & Clinical Cancer Research, vol. 37, no. 1, 2018. View at Google Scholar · View at Scopus
  27. W. L. Heaton, A. V. Senina, A. D. Pomicter et al., “Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion,” Leukemia, vol. 32, no. 11, pp. 2399–2411, 2018. View at Publisher · View at Google Scholar
  28. V. Jurisic, T. Terzic, S. Pavlovic, N. Colovic, and M. Colovic, “Elevated TNF-alpha and LDH without parathormone disturbance is associated with diffuse osteolytic lesions in leukemic transformation of myelofibrosis,” Pathology - Research and Practice, vol. 204, no. 2, pp. 129–132, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Dragoni, M. Reforgiato, E. Zuccolo et al., “Dysregulation of VEGF-induced proangiogenic Ca2+ oscillations in primary myelofibrosis-derived endothelial colony-forming cells,” Experimental Hematology, vol. 43, no. 12, pp. 1019–1030, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Moccia and G. Guerra, “Ca2+ Signalling in Endothelial Progenitor Cells: Friend or Foe?” Journal of Cellular Physiology, vol. 231, no. 2, pp. 314–327, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. U. Gianelli, C. Vener, P. R. Raviele et al., “VEGF expression correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders,” American Journal of Clinical Pathology, vol. 128, no. 6, pp. 966–973, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Wingelhofer, H. A. Neubauer, P. Valent et al., “Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer,” Leukemia, vol. 32, no. 8, pp. 1713–1726, 2018. View at Publisher · View at Google Scholar
  33. J. Grisouard, T. Shimizu, A. Duek et al., “Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN,” Blood, vol. 125, no. 13, pp. 2131–2140, 2015. View at Publisher · View at Google Scholar
  34. N. Fathi, G. Rashidi, A. Khodadadi, S. Shahi, and S. Sharifi, “STAT3 and apoptosis challenges in cancer,” International Journal of Biological Macromolecules, vol. 117, pp. 993–1001, 2018. View at Publisher · View at Google Scholar
  35. K. Takenaka, K. Shimoda, and K. Akashi, “Recent advances in the diagnosis and management of primary myelofibrosis,” The Korean Journal of Internal Medicine, vol. 33, no. 4, pp. 679–690, 2018. View at Publisher · View at Google Scholar
  36. F. Musumeci, C. Greco, I. Giacchell et al., “An Update on JAK Inhibitors,” Current Medicinal Chemistry, vol. 25, 2018. View at Publisher · View at Google Scholar
  37. J. Nangalia and A. R. Green, “Myeloproliferative neoplasms: from origins to outcomes,” Hematology Am Soc Hematol Educ Program, vol. 2017, no. 1, pp. 470–479, 2017. View at Google Scholar
  38. X. Cahu and S. N. Constantinescu, “Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations,” Current Heart Failure Reports, vol. 10, no. 4, pp. 335–343, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Yao, Y. Ma, Z. Hong et al., “Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm,” Leukemia, vol. 31, no. 10, pp. 2122–2131, 2017. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Tefferi, “Pathogenesis of myelofibrosis with myeloid metaplasia,” Journal of Clinical Oncology, vol. 23, no. 33, pp. 8520–8530, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Agarwal, K. Morrone, M. Bartenstein, Z. J. Zhao, A. Verma, and S. Goel, “Bone marrow fibrosis in primary myelofibrosis: Pathogenic mechanisms and the role of TGF-β,” Stem Cell Investigation, vol. 3, p. 5, 2016. View at Google Scholar · View at Scopus
  42. I. Ceglia, A. C. Dueck, and F. Masiello, “Preclinical rationale for TGF-beta inhibition as a therapeutic target for the treatment of myelofibrosis,” Experimental Hematology, vol. 44, no. 12, pp. 1138–1155.e113.
  43. H. Li, Q. Zhang, T. Chu et al., “Growth-inhibitory and apoptosis-inducing effects of tanshinones on hematological malignancy cells and their structure-activity relationship,” Anti-Cancer Drugs, vol. 23, no. 8, pp. 846–855, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. W. Wu, W. Chang, and C. Chen, “Cytotoxic Activities of Tanshinones Against Human Carcinoma Cell Lines,” American Journal of Chinese Medicine, vol. 19, no. 03n04, pp. 207–216, 1991. View at Publisher · View at Google Scholar
  45. Y. Wang, H. Lu, Y. Liu et al., “Cryptotanshinone sensitizes antitumor effect of paclitaxel on tongue squamous cell carcinoma growth by inhibiting the JAK/STAT3 signaling pathway,” Biomedicine & Pharmacotherapy, vol. 95, pp. 1388–1396, 2017. View at Publisher · View at Google Scholar
  46. Z. Chen, R. Zhu, J. Zheng et al., “Cryptotanshinone inhibits proliferation yet induces apoptosis by suppressing STAT3 signals in renal cell carcinoma,” Oncotarget , vol. 8, no. 30, pp. 50023–50033, 2017. View at Google Scholar · View at Scopus
  47. L. Gao, X. Zhou, Y. Zhang, Y. Cui, C. Yu, and S. Gao, “The anti-inflammatory activities of ethanol extract from Dan-Lou prescription in vivo and in vitro,” BMC Complementary and Alternative Medicine, vol. 15, no. 1, 2015. View at Publisher · View at Google Scholar
  48. S. Ma, D. Zhang, H. Lou, L. Sun, and J. Ji, “Evaluation of the anti-inflammatory activities of tanshinones isolated from Salvia miltiorrhiza var. Alba roots in THP-1 macrophages,” Journal of Ethnopharmacology, vol. 188, pp. 193–199, 2016. View at Publisher · View at Google Scholar · View at Scopus
  49. J. H. Feng, T. Zheng, and Z. H. Hou, “study on anti-tumor and anti-angiogenic activity of cryptotanshinone,” Chinese Journal of Biochemical Pharmaceutics, vol. 37, no. 3, pp. 30–33.
  50. Z. Zhu, Y. Zhao, J. Li et al., “Cryptotanshinone, a novel tumor angiogenesis inhibitor, destabilizes tumor necrosis factor-α mRNA via decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR,” Molecular Carcinogenesis, vol. 55, no. 10, pp. 1399–1410, 2016. View at Publisher · View at Google Scholar